Antisense Therapeutics Limited
ATHJF · OTC
6/30/2024 | 12/30/2023 | 6/30/2023 | 12/30/2022 | |
|---|---|---|---|---|
| Revenue | $2 | $1 | $1 | $0 |
| % Growth | 47.3% | 10.5% | 120.2% | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $2 | $1 | $1 | $0 |
| % Margin | 98.9% | 96.4% | 98.7% | 96.1% |
| R&D Expenses | $7 | $4 | $6 | $4 |
| G&A Expenses | $0 | $0 | $1 | $0 |
| SG&A Expenses | $2 | $2 | $1 | $2 |
| Sales & Mktg Exp. | $1 | $1 | $1 | $1 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $9 | $6 | $8 | $6 |
| Operating Income | -$7 | -$5 | -$6 | -$5 |
| % Margin | -403.9% | -394.9% | -598.1% | -1,067.5% |
| Other Income/Exp. Net | -$0 | -$0 | $0 | -$0 |
| Pre-Tax Income | -$7 | -$5 | -$6 | -$5 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$7 | -$5 | -$6 | -$5 |
| % Margin | -405.9% | -395.2% | -562.1% | -1,068.8% |
| EPS | -0.007 | -0.007 | -0.009 | -0.008 |
| % Growth | -6.1% | 28.3% | -17.9% | – |
| EPS Diluted | -0.007 | -0.007 | -0.009 | -0.008 |
| Weighted Avg Shares Out | 1,038 | 719 | 669 | 668 |
| Weighted Avg Shares Out Dil | 1,038 | 724 | 669 | 669 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$7 | -$5 | -$6 | -$5 |
| % Margin | -405.4% | -394.4% | -562.1% | -1,066.3% |